Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat), confirmed by a tissue test.
• People whose cancer has been classified as stage IVA+T3N2M0 using a specific staging system called AJCC 8th edition.
• People who are generally able to carry out daily activities with little to no limitation (confirm with trial site for exact definition).
• People whose blood cell counts are within acceptable ranges — including white blood cells, red blood cells, and platelets — as measured by a blood test.
• People whose liver function tests (ALT, AST, and bilirubin) are within acceptable ranges as shown by blood tests.
• People whose kidneys are working well enough, based on a calculation of how well the kidneys filter the blood.
• People who are willing to give written consent after being informed about the nature of the study.
• Women who could become pregnant and are sexually active must be willing to use effective contraception during the trial and for one year after the last dose of the study drug. Men who are sexually active with women who could become pregnant must also be willing to use effective contraception during the trial and for one year after the last dose.

Who may not be able to join:

• People who are younger than 18 or older than 65 years of age.
• People who test positive for Hepatitis B surface antigen with a high level of Hepatitis B virus detected in their blood.
• People who test positive for Hepatitis C virus antibodies.
• People who have an active autoimmune disease (a condition where the immune system attacks the body), with some exceptions such as type 1 diabetes, an underactive thyroid managed with medication, or certain skin conditions that do not need systemic (whole-body) treatment.
• People who have needed strong immune-suppressing medications (such as steroid tablets at a dose equivalent to more than 10mg of prednisone per day) within the 28 days before giving consent, with some exceptions for lower doses or inhaled/topical steroids.
• People who have had active tuberculosis (TB) within the past year (those whose TB was fully treated more than one year ago may still be eligible — confirm with trial site).
• People who have a known history of interstitial lung disease (a condition causing scarring or inflammation in the lungs).
• People who have received a live vaccine within 30 days before giving consent, or who plan to receive one in the near future.
• People who are currently pregnant or breastfeeding.
• People who have had another cancer diagnosed within the past five years, with some exceptions such as certain skin cancers and early-stage thyroid cancer.
• People who have a known allergy to large protein-based medicines or to any ingredient in the study drug, Adebrelimab.
• People who have a known history of HIV infection.
• People who have other significant health or personal circumstances — such as serious heart problems, active infections needing treatment, mental health conditions, or other factors — that the trial doctors believe could affect their ability to safely take part or to give informed consent.

Important: Always verify eligibility with the trial site directly before applying.